Yaqrit Overview

  • Founded
  • 2001

Founded
  • Status
  • Private

  • Employees
  • 13

Employees
  • Latest Deal Type
  • PE Growth

  • Financing Rounds
  • 5

Yaqrit General Information

Description

Operator of a clinical-stage life sciences company intended to develop end-to-end applications to prevent, treat and reverse advanced liver disease. The company integrates technical expertise, clinical trial design and execution with its global collaborator network to accelerate the development of the programs for severely ill patients with cirrhosis or Acute-on-Chronic Liver Failure (ACLF) to include patients with the complication of cirrhosis, Non-Alcoholic Steatohepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD), which affects a significant proportion of the population in developed economies, enabling to deliver clinical and commercial success.

Contact Information

Website
www.yaqrit.com
Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Drug Discovery
Other Industries
Discovery Tools (Healthcare)
Primary Office
  • The Elms Courtyard Bromesberrow
  • Ledbury HR8 1RZ
  • England, United Kingdom

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Yaqrit Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Yaqrit‘s full profile, request access.

Request a free trial

Yaqrit Patents

Yaqrit Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201013785-D0 Treatment Ceased 17-Aug-2010 000000000
ES-2700783-T3 Treatment Active 17-Aug-2010 000000000
US-10639346-B2 Treating hyperammonemia, reducing plasma ammonia with tlr4 antagonists Active 17-Aug-2010 000000000 0
US-20180256669-A1 Treating renal and liver dysfunction with tlr4 antagonists Granted 17-Aug-2010 000000000 0
US-9889176-B2 Treating renal and liver dysfunction with tlr4 antagonists Active 17-Aug-2010 A61K38/10 0
To view Yaqrit’s complete patent history, request access »

Yaqrit Executive Team (5)

Name Title Board Seat Contact Info
Daniel Green Chief Executive Officer & Board Member
Sandeep Nanda Chief Financial Officer & Board Member
Rajiv Jalan Ph.D Founder, Chief Scientific Officer & Board Member
Priyesh Khanna President & Chief Commercial Officer
You’re viewing 4 of 5 executive team members. Get the full list »

Yaqrit Board Members (7)

Name Representing Role Since
000000 00000 Yaqrit Chief Executive Officer & Board Member 000 0000
00000 0000000 00 Yaqrit Board Member 000 0000
0000 0000000 Self Board Member 000 0000
0000000 00000 Yaqrit Chief Financial Officer & Board Member 000 0000
0000000 000000 Yaqrit Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Yaqrit Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Yaqrit Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Yaqrit‘s full profile, request access.

Request a free trial